Cost-effectiveness of 82-Rubidium PET myocardial perfusion imaging for the diagnosis of myocardial ischemia depending on the prevalence of coronary artery disease.

"Declarations Ethics approval and consent to participateThe study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. All patients provided signed informed consent; the full description of the study design has been registered on clinicaltrials.gov (NCT01679886; https://clinicaltrials.gov/ct2/show/NCT01679886). The French Institutional Review Board approved the study protocol (IRB number: 2012-A00552-41). Consent for publicationNot applicable. Competing interestsFabien Hyafil is Consultant for Naogen, Curium Pharma, Blue Earth Diagnostics, Novo Nordisk and shareholder of Naogen. The other authors declare no competing interests. Competing interests Fabien Hyafil is Consultant for Naogen, Curium Pharma, Blue Earth Diagnostics, Novo Nordisk and shareholder of Naogen. The other authors declare no competing interests."

"Funding This research was funded by a grant from the French Ministry of Health (Programme Hospitalier de Recherche Clinique 2011 AOM11066)."

"Trial registration RUBIS Trial registration: NCT01679886, Registered 03 September 2012, https://clinicaltrials.gov/ct2/show/NCT01679886. Trial registration"